Endometrial Carcinoma Molecular Classification and Barriers to Implementation, Possible Solutions, and the Implications for Ongoing Clinical Trials.

Abstract

Molecular classification of endometrial carcinoma provides important prognostic and predictive information and ongoing clinical trials are investigating different treatment paradigms and therapy de-escalation. Despite its benefits, there is variability in the application of molecular classification worldwide, including in Canada. A digital survey was distributed to gynaecologic pathologists in 13 Canadian academic pathology departments, and areas of homogeneity and variability in practice for endometrial carcinoma molecular classification were identified. Perceived barriers to universal application included resource restrictions and ambiguity of management implications. Focused research, knowledge translation, and guideline development will aid in more consistent implementation/application.